Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Pharma Stock to Watch: Drug maker secures US FDA nod for Perampanel tablets, eyes Q3 launch

3 October 2026 · By · Wire by Fusion42

Published

3 October 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at zeebiz.com →

◆ Verified

Fusion42 · 4 October 2026 · Fusion42 review

Aurobindo Pharma received final FDA approval to manufacture and market Perampanel tablets in multiple strengths, with plans to launch in Q3 FY27. The drug addresses seizures related to epilepsy and has an estimated market size of $67 million for the past year.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 3 Oct 2026 and 5 Oct 2026.

◆ ◆ The Wire takeaway

You can enter the US epilepsy treatment market more confidently now that Aurobindo Pharma’s FDA approval clears your path. Expect competition to rise around Perampanel tablets and adjust your US launch or partnership efforts accordingly.

◆ Coverage

2 sources · first reported 3 Oct 2026 · latest 5 Oct 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalpharmaepilepsy-treatmentperampanelmarket-launch